Investor profile
Broadview Ventures
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Broadview Ventures is a mission-driven investment organization whose primary goal is to improve human health in the areas of cardiovascular disease and stroke. Established in 2009 to address the translational gap, Broadview provides seed and early-stage equity investments in companies developing innovative technologies — spanning therapeutics, devices, diagnostics, and digital health — for cardiovascular and neurovascular indications. The firm invests in great science backed by outstanding management teams, focusing on novel mechanisms and innovative technologies, and leverages access to global thought leaders to identify and address development hurdles. Broadview is funded entirely by the Leducq Charitable Trust as an evergreen vehicle, acting as a catalyst investor at critical points in development with a long investment horizon. Its affiliated fund, Longview Ventures ($100M over 10 years, launched 2018), makes follow-on investments in select Broadview portfolio companies at the clinical stage (Series B–C), complementing Broadview's dedication to Seed and Series A financings. The portfolio spans a global footprint across North America, Europe, and Israel, and Broadview's investments have been leveraged 16.5x by co- and follow-on investments, generating over $2.1 billion in total investment dollars.
Notable quotes
“For every dollar invested by Broadview, its portfolio companies have raised seven additional dollars in co-investments, follow-on funding, and grants.”
“Tom's promotion demonstrates Broadview's strong commitment to the career progression and recognition of its investment team members. I look forward to continued partnership with Tom in his expanded leadership role across the Broadview and Longview organizations.”
“Broadview Ventures operates as a for-profit, mission-driven, venture philanthropic model — an early-stage (Seed–Series A) investor with CVD/NVD focus acting as a catalyst investor at a critical point in development with a long investment horizon.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Relief Cardiovascular | Series A | $12m | 2025-01-01 |
| Alveron Pharma | Seed | $5m | 2024-12-01 |
| CorFlow Therapeutics | Series B | $48m | 2024-09-01 |
| IsomAb | Seed | $9m | 2024-02-01 |
| Comanche BioPharma | Series B | $75m | 2023-02-01 |
| Basking Biosciences | Series B | $55m | 2023-02-01 |
| Puzzle Medical Devices | Series A | $25m | 2023-02-01 |
| CroíValve | Series B | $16m | 2024-08-01 |
| Cardiosense | Series A | $15m | 2022-12-01 |
| Renovacor | Series A | — | 2019-01-01 |
Frequent co-investors
Fit check
Is Broadview Ventures a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit